secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0001193125-22-121628
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q1 revenue $206.4M (+45% YoY); lowers FY2022 revenue guidance on COVID decline
--------------------------------------------------------------------------------

- Record Q1 revenue of $206.4M (+45% YoY); GAAP EPS $0.81, adjusted EPS $0.92.
- Base business grew 37% YoY; gene therapy revenue up >100%.
- FY2022 revenue guidance lowered to $770-800M (from $800-830M) due to lower COVID demand.
- Base business revenue growth guidance raised to 24%-31% (from 20%-22%).
- Cash $584.6M at quarter end; gross margin improved 190 bps to 60.1%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312522121628/0001193125-22-121628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312522121628/d342731d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-121628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer